Advertisement

Topics

Companies Related to "High-sensitivity Troponin T in Acute Myocardial Infarction After Cardiac Valvular Surgery" [Most Relevant Company Matches] RSS

18:51 EDT 19th June 2019 | BioPortfolio

Here are the most relevant search results for "High-sensitivity Troponin T in Acute Myocardial Infarction After Cardiac Valvular Surgery" found in our extensive corporate database of over 50,000 company records.

Showing "High sensitivity Troponin Acute Myocardial Infarction After Cardiac" Companies 1–25 of 5,200+

Extremely Relevant

Response Biomedical Corp

Response Biomedical is commercializing a new class of diagnostic with the world's only immunoassay platform that provides lab quality information in a matter of minutes, anywhere, every time. RAMP® tests are commercially available for three cardiac markers used in the early detection of heart attack, environmental detection of West Nile virus, and biodefense applications including the detection o...


STENTYS S.A.

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapts to the...

t2cure GmbH

t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases like myocardial infarction or peripheral artery occlusive disease.


OtiTopic, Inc.

OTITOPIC™ (http://otitopic.com/) is a privately funded drug development company in clinical stage with a track record of success in Pharmaceutical product drug delivery and drug device development. ASPRIHALE™ is a proprietary Dry Powder Inhalation of aspirin formulation delivered via portable dry powder inhaler (DPI) that is expected to enter the...

Relevant

Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company’s most advanced drug candidate, AMRS00...

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...

Amorcyte, Inc.

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI eve...

Apogenix GmbH

The biopharmaceutical company Apogenix, located in Heidelberg, Germany, develops innovative drug candidates which exert their therapeutic effect by modulating the programmed cell death (apoptosis). The therapeutic focus lies on acute cerebro- and cardiovascular diseases (e.g. myocardial infarction) where apoptosis is abnormally increased, and on cancer diseases where apoptosis is abnormally decrea...

BIOHEART INC.

Bioheart, Inc.Bioheart, Inc. is focused on the discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases such as congestive heart failure (“CHF”) secondary to myocardial infarction (“MI”) and cardiovascular electrical abnormalities. The Company believes that its products hold the potential to revolutionize the treatment of card...

Medivance, Inc.

During the 1990’s, a growing number of animal studies showed evidence that modification of patient temperature could be a critical step in improving patient outcomes after a variety of tragic events, such as stroke, cardiac arrest, and acute myocardial infarction or heart attack. Imprecise and unacceptable methods of controlling patient temperature limited the progression from animal studie...

Arrhythmia Research Technology

Arrhythmia Research Technology, Inc. (ART) was founded in 1981 specifically to capitalize on the marketing of certain patents or licenses concerning the application of signal-averaged electrocardiography (SAECG) for the detection of cardiac late potentials. Late potentials have been shown to be an indicator of risk for ventricular tachycardia (VT) which can degenerate into ventricular fibrillati...

Lev Pharmaceuticals

We are a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Our product candidates are based on C1-esterase inhibitor (C1-INH), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. We initiated a Phase III clinical trial of our lead product...

Ikaria, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering...

Ikaria Holdings, Inc.

Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering...

NeuroVive Pharmaceutical AB

NeuroVive Pharmaceutical AB (www.neurovive.com) is a Swedish drug development company whose primary mission is to develop drugs for the treatment of acute brain injury, reperfusion injury in myocardial infarction and other acute injuries where mitochondrial energy production is critical for clinical outcome. The research and development program focuses on developing new variants of cyclophilin i...

Labmaster Oy

We focus on delivering innovative diagnostic tools for applications in functional food research and routine clinical diagnostics.The technologies used in products include robust enzyme ligand immunoassay (ELISA), sensitive and robust time-resolved fluorescence immunoassay (TR-FIA) and PCR-based diagnostics. The products are used in functional foods research, routine diagnostics of coeliac diseases...

BioLineRx Ltd.

BioLineRx Ltd. is a publicly traded (TASE:BLRX) biopharmaceutical development company based in Jerusalem, Israel. BioLineRx is dedicated to identifying, in-licensing and developing therapeutic candidates for unmet medical needs or that have advantages over currently available therapies. BioLineRx’s current development pipeline consists of three clinic...

Coagulation Diagnostics Incorporated

Coagulation Diagnostics, Inc. (CDI) develops proprietary diagnostic tests for hypercoagulability, or the tendency to form blood clots. The primary applications for the Company's diagnostic tests include monitoring of novel anticoagulants, assessing the risk of acute myocardial infarction, diagnosing possible reactivation of ischemia, and assessing the risk of clotting following invasive cardiovasc...

Stemedica Cell Technologies Inc.

Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class, allogeneic, adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government-licensed manufacturer of clini...

Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The company works to prevent the worse...

Ischemix, Inc.

Ischemix is a privately-held, clinical-stage pharmaceutical company developing novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. The initial focus of the Company is the prevention of acute kidney injury and cardiac injury in patients undergoing cardiac catheterization procedures. Ischemix’ lead product...

PrognostiX, Inc.

PrognostiX, Inc. is a medical diagnostics company. Our technology is based on the unique role of inflammatory processes in major disease areas including cardiovascular, respiratory, neurodegenerative disease and obesity. We are developing new and innovative diagnostic products that enhance and improve medical care.PrognostiX is marketing the CardioMPO™ ELISA based test kit for in vitro diagnosti...

Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that inc...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

DecImmune Therapeutics

DecImmune Therapeutics was founded by Michael Carroll PhD (The Immune Disease Institute, Harvard Medical School), and Francis Moore Jr. MD (Brigham and Women’s Hospital, Harvard Medical School). Drs. Moore and Carroll discovered the epitope of non-muscle myocin heavy chain II (“N2”) that becomes exposed on vascular cells during hypoxia. During ...


More From BioPortfolio on "High-sensitivity Troponin T in Acute Myocardial Infarction After Cardiac Valvular Surgery"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks